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Abstract
Background: Identification of genes that are causally implicated in oncogenesis is a major goal in cancer research. An
estimated 10–20% of cancer-related gene mutations result in skipping of one or more exons in the encoded transcripts.
Here we report on a strategy to screen in a global fashion for such exon-skipping events using PAttern based Correlation
(PAC). The PAC algorithm has been used previously to identify differentially expressed splice variants between two
predefined subgroups. As genetic changes in cancer are sample specific, we tested the ability of PAC to identify aberrantly
expressed exons in single samples.
Principal Findings: As a proof-of-principle, we tested the PAC strategy on human cancer samples of which the complete
coding sequence of eight cancer genes had been screened for mutations. PAC detected all seven exon-skipping mutants
among 12 cancer cell lines. PAC also identified exon-skipping mutants in clinical cancer specimens although detection was
compromised due to heterogeneous (wild-type) transcript expression. PAC reduced the number of candidate genes/exons
for subsequent mutational analysis by two to three orders of magnitude and had a substantial true positive rate.
Importantly, of 112 randomly selected outlier exons, sequence analysis identified two novel exon skipping events, two novel
base changes and 21 previously reported base changes (SNPs).
Conclusions: The ability of PAC to enrich for mutated transcripts and to identify known and novel genetic changes confirms
its suitability as a strategy to identify candidate cancer genes.
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Introduction
Cancer is driven by mutations in genes that control the
proliferation of cells, their survival and their integrity. Screens
aimed at identifying such cancer genes often use chromosomal
location and/or functional properties to select candidates genes for
subsequent mutation analysis [1–4]. Although many candidate
cancer gene loci have been identified, the labor-intensive mutation
analysis severely hampers finding the corresponding cancer gene.
Other gene search strategies have focused on aberrant gene
expression patterns to identify candidates. For example, gene
mutants that result in premature termination codons were
identified by screening for genes that were specifically expressed
following chemical inhibition of nonsense mediated RNA decay
[5]. Furthermore, fusion genes in prostate cancer were identified
by screening for outliers in a large cohort of gene-expression
profiles [6].
Human cancer gene mutations frequently result in the skipping
of one or several exons from the encoded transcripts [7–9]. Exon-
skipping mutations may be caused by nucleotide substitutions
within the consensus splice sites or by deletions that span entire
exons. In addition, exon-skipping mutations may be caused by
relatively small intragenic insertions, deletions or duplications.
Even though exon-skipping mutations represent an estimated 10–
20% of all cancer-related gene mutations [4,9–12], no high
throughput method has been available to screen for such
mutations. Here, we describe Pattern Based Correlation (PAC)
as an approach to identify candidate cancer genes by screening for
exon-skipping events in a global fashion. Detailed mutation
analysis is then restricted only to the PAC-identified outlier exons.
As a proof-of-principle, we demonstrate the efficacy of the PAC
strategy on previously identified exon-skipping mutations in breast
cancer cell lines and in clinical brain tumor samples. We also
demonstrate that PAC can identify novel exon skipping events
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with underlying genetic changes in known cancer genes and in
randomly-selected PAC-identified outlier exons.
Results
Outlier exon identification by Pattern Based Correlation
(PAC)
In this study we have developed a new approach to screen exon-
skipping events in human cancer samples. Because mutations in
cancer often are highly heterogeneous with respect to their
intragenic location, individual tumors often express unique RNA
species. Screening for mutations that result in skipping of one or
more exons in the encoded transcript therefore requires screening
for unique, exon-skipped, transcripts within a specific sample
cohort. Briefly, exon-level expression profiles are generated using
Affymetrix Human Exon Arrays, which determine the expression
level of virtually all exons present in the human genome. The
PAttern based Correlation (PAC) algorithm is then used to
calculate the predicted expression level of each exon (or probe set).
We then identify outlier exons by subtracting the predicted
expression level of exons from their measured expression level,
with values equaling zero when the measured expression level of
an exon was similar to its predicted expression level (formulated in
detail under Methods). The PAC algorithm has been used to
identify differential splicing between predefined groups [13]. In
this study, we have tested the PAC algorithm for its ability to
identify aberrantly expressed exons in single samples of a well
defined cohort of cell lines or tumors. PAC effectively normalizes
the variability in gene expression levels between samples and, in a
single sample, normalizes the variability in signal intensity between
probe sets of the same transcript (Fig. 1).
PAC detects exon-skipping events in breast cancer cell
lines
We tested the feasibility of the PAC strategy on a panel of 12
human breast cancer cell lines that had been screened for
mutations in seven tumor suppressor genes: BRCA1, CDH1,
MAP2K4, PTEN, p16, p53 and RB1 [14–18], and unpublished
results). Mutation analysis was performed by sequencing of the
complete coding sequences of the genes and analysis of all
mutations on both genomic gene fragments and transcripts.
Together, the 12 cell lines contained seven gene mutants that
should be detectable by PAC, as they resulted in the skipping of
eight exons from among four tumor suppressor genes (mutations
are detailed in Table 1). We have explored the PAC strategy at
different cut-off levels, identifying outlier exons that were
expressed less than 16-fold, 8-fold, 4-fold, 2.8-fold and 2.5-fold
than their predicted expression level (i.e. PAC values of -4.0, -3.0, -
2.0, -1.5 and -1.3, respectively). Outlier exons were identified
without prior knowledge of the mutation data.
From the total of 3.4 million core probe sets that we assayed for
the 12 cell lines (290,000 core probe sets per sample), PAC
identified 21,151 (0.6%) outlier probe sets at PAC value 24.0 and
94,590 (2.8%) outlier probe sets at PAC value 21.3 (Fig. 2A). All
probe sets at PAC values ,22.0 (34,137 probe sets corresponding
to 31,357 exons and 10,247 genes) are listed in supplementary
data Table S1. When all PAC values are plotted in a frequency
histogram, a tail towards the negative end is observed (Fig. 2A).
This skewed distribution gives a rough estimation of the false
positive rate at the various PAC levels. PAC of the seven fully
characterized tumor suppressor genes in the 12 cell lines involved
analysis of 1,200 exons (1,752 probe sets). PAC correctly detected
six of the eight skipped exons when using PAC value 24.0, seven
skipped exons were detected at PAC value 22.0 and all eight
skipped exons were detected at PAC value 21.3 (Fig. 2C).
Importantly, the number of false positive outlier exons was
substantially reduced at PAC value 24.0 as compared to PAC
value 21.3, resulting in an increase of the true positive rate from
9% to 24% of the identified outlier exons (Fig. 2D). For
comparison, random sampling of 24/1200 exons has a .85%
probability of not finding any true positive mutation and only a
,1028 chance of finding 6 or more. For the known cancer genes
used in our study, the true positive rate of our approach thus by far
exceeds random exon selection. In this respect, the reduction of
the number of false positive candidate genes may initially be far
more beneficial for a gene search project than accurate
identification of all true positive outlier exons. Together, our
results show that the PAC strategy is reliable in detecting exon-
skipping mutants in cancer cell lines.
Figure 1. PAC detection of an exon-skipping PTENmutant. (A) Normalized expression data of all exons within the PTEN gene. Each exon probe
set is represented by a dot in the solid line; multiple probe sets may be directed against the same exon. (B) PAC normalizes the variability in gene
expression levels between samples and, in a single sample, the variability in signal intensity between probe sets of the same transcript. PAC
calculation therefore allows rapid detection of skipping of PTEN exon 4 in breast cancer cell line MDA-MB-468 due to a PTEN c.253+1G.T splice site
mutation that we previously had identified [17].
doi:10.1371/journal.pone.0003007.g001
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Table 1. Detection of exon-skipping mutants by PAC.
Tumor sample Gene Mutation mRNA PAC detection
OCUB-F CDH1 c.49_163del r.49_163del115 (Ex2) detected
MDA-MB-134VI CDH1 c.688_832del r.688_832del145 (Ex6) detected
MPE600 CDH1 c.1138_1320del r.1138_1320del183 (Ex9) detected
CAMA-1 CDH1 c.1712-1G.A r.1566_1712del147 (Ex11) detected
MDA-MB-468 PTEN c.253+1G.T r.210_253del44 (Ex4) detected
MDA-MB-453 p53 c.994_1182del r.994_1182del189 (Ex10-11) detected
HCC1937 RB1 c.2212_2325del r.2212_2325del114 (Ex22) detected
Glioblastoma 67 EGFR c.89_889del r.89_889del801 (Ex2-7) not detected
Glioblastoma 96 EGFR c.89_889del r.89_889del801 (Ex2-7) detected
Glioblastoma 142 EGFR c.89_889del r.89_889del801 (Ex2-7) detected
Glioblastoma 149 EGFR c.89_889del r.89_889del801 (Ex2-7) not detected
Glioblastoma 163 EGFR c.89_889del r.89_889del801 (Ex2-7) not detected
Glioblastoma 164 EGFR c.89_889del r.89_889del801 (Ex2-7) not detected
Stated are mutations that result in the expression of an aberrant transcript variant in breast cancer cell lines (top) and clinical glioblastoma samples (bottom). All
mutations were determined by sequencing genomic DNA fragments as well as transcripts, where the cDNA sequence c.1 corresponds to the adenosine residue of the
ATG initiation codon in the Genbank reference sequence. Genbank accession numbers: Z13009, NM_000314, NM_000546, NM_000321 and NM_005228.3 for CDH1,
PTEN, p53, RB1 and EGFR, respectively. Detection of the mutations by PAC was at PAC value 21.3.
doi:10.1371/journal.pone.0003007.t001
Figure 2. Performance of PAC to detect exon-skipping mutants. (A) and (B) Total number of PAC-detected outlier probe sets from among
290,000 core probe sets in 12 breast cancer cell lines and in 14 glioblastomas, respectively. (C) Number of skipped exons detected by PAC as a
percentage of all eight skipped exons present in the breast cancer cell lines, or as a percentage of the 36 skipped EGFR exons present in the
glioblastomas (see Table 1). (D) Total number of outlier exons (true plus false positives) and number of true positive outlier exons detected by PAC
among the seven tumor suppressor genes and the EGFR oncogene. True positive outlier exons include all PAC detected skipped exons and two
missense mutations (PTEN c.274G.C in CAMA1, MAP2K4 c.551C.G in MDA-MB-134VI).
doi:10.1371/journal.pone.0003007.g002
Cancer Gene Identification
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PAC performance in samples with heterogeneous
transcript expression
Similar to other genetic screening methods, PAC is most suited
to detect homozygous genetic changes. For example, the lowest
PAC value when 50% wild-type transcripts are present (as may be
the case for a heterozygous genetic change) is 21.0. The
somewhat compromised detection of skipped exons at PAC value
24.0 as compared to PAC value 21.3 (i.e. six vs. all eight skipped
exons) in our panel of breast cancer cell lines therefore may have
been caused by the expression of a second aberrant transcript that
still includes (part of) the exon. Indeed, a second CDH1 transcript
length of minor intensity was detected in CAMA-1 (Fig. 3A), the
splice site mutant that had been detected only at PAC value 21.3.
To further asses the performance of PAC in samples with
heterogeneous (wild-type and mutant) transcript expression, we
performed PAC on 14 clinical glioblastoma specimens (selected to
contain .70% tumor nuclei) that had genomic amplifications of
the EGFR oncogene. Glioblastomas with EGFR amplifications
frequently carry an intragenic deletion of exons 2 through 7,
resulting in expression of the constitutively active EGFRvIII
isoform [8,19]. However, glioblastomas expressing the EGFRvIII
isoform also frequently express wild-type EGFR transcripts. This
heterogeneous EGFR expression is related to amplification of the
EGFR locus prior to the deletion of exons [20], although non-
malignant cells in the glioblastoma specimens may also express
EGFR. Of the fourteen glioblastoma samples used in this study, six
expressed EGFRvIII (a total of 36 skipped exons) of which five also
expressed significant levels of wild-type EGFR transcripts as
determined by quantitative Real-Time PCR (qPCR) (Fig. 3B)
(insufficient RNA remained of the sixth sample with EGFRvIII
expression to perform qPCR).
From the total of 4.1 million core probe sets that we assayed for
these 14 samples (290,000 core probe sets per sample), PAC
identified 1,646 (0.04%) outlier probe sets at PAC value 24.0 and
39,936 (1.0%) outlier probe sets at PAC value21.3 (Fig. 2B). PAC
thus identified three to ten-fold less outlier exons in the
glioblastomas as compared to the breast cancer cell lines
(Fig. 2A). All probe sets at PAC values ,22.0 (11,287 probe
sets, corresponding to 10,903 exons and 6,264 genes) are listed in
supplementary data Table S1. This smaller number of outlier
exons in the glioblastomas may be related to their homogeneous
histopathology and their highly similar gene expression profiles
[13,21], to the presence of non-neoplastic cells in the tumor
samples, or may reflect sampling biases due to small cohort sizes.
PAC of the EGFR gene in the 14 glioblastomas involved the
analysis of 392 exons (434 probe sets). PAC detected two of six
EGFRvIII expressing tumors (12 of the 36 skipped exons) at PAC
values 22.0 and lower (Table 1 and Fig. 2C). Of the two
glioblastomas with EGFRvIII that had been detected by PAC, one
had significantly (i.e. .5 fold) more mutant than wild-type EGFR
transcripts. In this tumor, the Ct value difference was .2 between
qPCR fragments inside (measuring only wild-type EGFR tran-
scripts) and outside (measuring both wild-type and EGFRvIII
transcripts) the EGFR exon 2–7 deletion region (Fig. 3B). The
other glioblastoma had a similar expression level difference
between wild-type and EGFRvIII transcripts (Ct value difference
of ,1.5) as the three glioblastomas that had not been detected by
PAC, but had lower overall EGFR transcript levels. It appears that
PAC detection of the EGFRvIII isoform is determined by the
overall expression level of EGFR transcripts in combination with
the ratio of EGFRvIII and wild-type EGFR transcripts, where
samples with too high EGFR transcript levels may escape PAC
detection due to saturation of the probe sets involved. These
results show that the PAC strategy can detect exon-skipping
mutants in clinical cancer specimens if the ratio mutant/wild-type
transcript level is high and when probe sets are within the linear
detection range of the microarray.
PAC performance in detecting recurrent outlier exons
PAC performance can also be challenged by recurrent outlier
exons. Such frequently skipped exons will result in an underes-
timation of the exon/transcript ratio in the PAC algorithm and so
increase PAC values. We therefore evaluated the performance of
PAC in detecting recurrent outlier exons by reiterated replace-
ment of EGFRvIII expressing samples with samples that expressed
only wild-type EGFR (Fig. 4A). When six of 14 samples express
EGFRvIII, the deletion of exons 2–7 in GBM67 is not detected by
PAC. PAC values indeed decreased with decreasing ratios of wild-
type versus mutant samples. However, the decrease was relatively
small and resulted in the identification of only one of the six
deleted exons once the ratio had dropped to one mutant sample
among 14 samples. We also simulated PAC detection of recurrent
mutations with two breast cancer cell lines, of which HCC1937
had skipped RB1 exon 22, and we were already able to identify the
mutant from among two samples up to even five mutants from
among six samples (Fig. 4B). These simulation experiments
Figure 3. Compromised detection due to heterogeneous
transcript expression. Skipping of CDH1 exon 11 in breast cancer
cell line CAMA-1 was only detected at PAC value 21.3, likely due to
expression of a second aberrant transcript variant (*) that was detected
by conventional RT-PCR. (B) Expression of EGFR transcripts was detected
in glioblastoma samples by Real-Time RT-PCR, using primers designed
to anneal inside the exon 2–7 deletion region of the EGFRvIII isoform
(gray bars) or outside the deletion region (black bars). Differences in Ct
values between the two transcript fragments are indicative for EGFRvIII
isoform expression levels. All five samples with the EGFRvIII isoform also
expressed significant amounts of wild-type EGFR transcripts, likely
compromising outlier detection by PAC (indicated by ‘‘detected’’ and
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indicate that PAC performs well in identifying recurrent exon-
skipping mutations.
Detection of nucleotide substitutions and novel genetic
changes by PAC
The performance of PAC was further evaluated by analysis of
outlier exons selected from all candidates at PAC value #22.0 in
breast cancer cell lines and clinical glioblastoma samples. In total,
44 and 68 outlier exons were screened in breast cancer cell lines
and glioblastoma samples respectively. Sequence analysis of PCR
amplified outlier exons identified two novel exon skipping events
and two novel genetic base changes in glioblastoma samples, as
well as a number of previously reported base changes (homozy-
gous SNPs) in breast cancer cell lines (n = 5) and glioblastomas
(n = 16). RT-PCR experiment results are detailed in supplemen-
tary data Table S2.
The majority of genetic changes identified by PAC were single
nucleotide changes, both in breast cancer cell lines (five known
SNPs) and in glioblastomas (two novel base changes and 16 known
SNPs). Moreover, two out of ten previously identified oncogenic
point mutations that did not result in exon skipping events were
also PAC detected in our cohort of breast cancer cell lines:
MAP2K4 c.551C.G in MDA-MB-134VI and PTEN c.274G.C
in CAMA-1; [16,17] (Fig. 5). Single nucleotide mismatches have
been used to define hybridization specificity on other Affymetrix
microarray platforms. By analogy, single nucleotide substitutions
in cancer may also cause reduced hybridization to the probes on
the microarray and thus be detected as outlier exons by PAC.
Indeed, all of the PAC detected base changes and SNPs were
centrally localized within the probe set selection region and
overlap with several of its individual probes (Fig. 5).
One of the PAC identified novel exon skipping events was
predicted to result in a deletion of the four 39 end exons of EGFR
(Fig. 6A). This exon-skipping event was due to a genomic deletion
as determined using semi quantitative PCR on genomic tumor
DNA. Compared to the 59 end of the EGFR locus in GBM157, the
39 end showed less amplification (DCt 22.5) whereas other
samples showed equal amplification between the 59 and 39 end of
the gene (DCt 0.361.9). Similar 39 deletions in EGFR have been
observed previously in gliomas [19]. The second exon-skipping
event predicted by PAC would result in a deletion of exon 30 in
the FCGBP cDNA (Fig. 6B). This deletion will cause a frameshift
that is predicted to result in a truncated protein. The absence of
exon 30 was confirmed by RT-PCR and sequence analysis
(Fig. 6C). Novel identified single base changes include a single base
change 1934C.G (S645C) in the EGFR gene, (Fig. 6A and D),
Figure 4. Performance of PAC to detect recurrent outlier exons.
(A) Simulation experiment to determine PAC performance in detecting
recurrent exon-skipping events among clinical glioblastoma samples,
where mutant samples express the EGFRvIII isoform with deletion of
exons 2 through 7. The cohort of 14 glioblastomas included six mutant
samples that were replaced by wild-type samples through reiteration,
based on their position from left to right in Fig. 3B. Deletion of EGFR
exon 6 in sample GBM67 was detected only as unique mutant sample.
(B) Simulation experiment to determine PAC performance in detecting
recurrent exon-skipping events among breast cancer cell lines, using
the wild-type cell line CAMA-1 and the RB1 exon 22 deletion mutant
HCC1937. The two cell lines were analyzed under various cohort sizes,
with either the wild-type or the mutant cell line as single sample. The
mutant sample was still detected at PAC value 22.0 with five recurrent
mutants among six samples. The average expression level of RB1 exon
22 dropped below PLIER 50 when more than five mutants were
simulated, precluding PAC analysis (see Materials and Methods).
doi:10.1371/journal.pone.0003007.g004
Figure 5. Identification of nucleotide substitutions by PAC. (A)
PAC predicts skipping of the 59 end of PTEN exon 5 in the CAMA-1
breast cancer cell line. This cell line contains a nucleotide substitution
within the identified exon. This base change does not induce exon
skipping but is centrally located within all three probes of the probe set
(B). The central location suggests this mutation causes a reduced
affinity to the probes on the exon-array.
doi:10.1371/journal.pone.0003007.g005
Cancer Gene Identification
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and a single base change 946G.A (G316R) in the TLE2 gene
(Fig. 6E). The G316R (946G.A) mutation in TLE2 is rendered
‘‘pathological’’ by PMut (mmb2.pcb.ub.es:8080/PMut/) and ‘‘not
tolerated’’ by SIFT BLink (blocks.fhcrc.org/sift/SIFT_BLink_-
submit.html). In summary, the novel exon skipping events and
base changes identified by analysis of a selected set of outlier exons
confirms the suitability of PAC to identify candidate cancer genes.
Discussion
We have developed an approach that uses PAttern based
Correlation (PAC) to screen for cancer gene mutations that cause
exon skipping in the encoded transcripts. We demonstrate that PAC
correctly detected all of seven previously identified exon-skipping
mutants in breast cancer cell lines and two of six mutants in clinical
glioblastoma samples. The true and false positive rates were
determined at various stringency levels. Importantly, PAC identified
a number of novel genetic changes, including those affecting
splicing, that previously had gone undetected. These novel genetic
changes are either in known cancer genes (EGFR), result in a
frameshift (FCGBP) or are rendered ‘‘not tolerated’’ by gene
prediction algorithms PMut and SIFT BLink (TLE2). Additional
experiments are required to determine whether changes in the novel
candidate cancer genes (FCGBP and TLE2) are indeed oncogenic. A
significant number of nucleotide substitutions that are located
within the probe set selection region are also PAC detected (Fig. 5).
Our results thus classify PAC as a reliable approach to screen for
candidate cancer genes in a global fashion.
Gene expression profiling at the level of individual exons has only
recently become feasible through the release of exon arrays. Here,
we have explored the efficacy of PAC to identify exon-skipping
mutants, but the strategy may also be used to deduce the primary
structure of gene transcripts [13,22]. It is important to note that the
PAC algorithm, detailed under Materials andMethods, is in essence
a simple formula that predicts outlier exons based on fold change
differences between measured and predicted exon expression levels.
Other approaches can also be used to identify outliers (e.g. .n
standard deviations from the mean expression level) but need to
account for the non-linearity in gene expression levels between
samples (especially for cancer genes) and the limited sample size.
Because of the high true positive rates obtained by PAC, we did not
further explore alternative statistical approaches.
The PAC algorithm is independent of array platform or
organism, allowing application of the PAC strategy in a wide
variety of biological systems. Several algorithms for exon-level
expression profiling are commercially available, including Strata-
gene ArrayAssist (www.stratagene.com), Partek Genomics Suite
(www.partek.com) and Genomatix Suite (www.genomatix.de).
Although each of these software packages is relatively straight-
forward, important advantages of PAC are that it allows detection
of unique outlier exons without any prior knowledge of the
encoding gene or its transcript structure and that it does not
require predefined subgroups of samples with differential expres-
sion of the outlier exons.
As with any global screening strategy, PAC has its preconditions
for detecting outlier exons. First and foremost, identification of
Figure 6. PAC Identification of novel genetic changes. (A) PAC detection of novel genetic changes in EGFR. PAC predicted skipping of the last
four exons of GBM157 and the 59 end of exon 17 in GBM172. Semi-quantitative PCR on genomic DNA confirmed the deletion in GBM157 (not shown).
(B) PAC predicts skipping of exon 30 in the FCGBP gene in GBM60. (C) RT-PCR confirmed the FCGBP exon skipping event in GBM60; other tumors did
not show this exon skipping. (D) Direct sequencing identified a single base change in EGFR in GBM172 (as predicted by PAC, see Fig. 6A). (E)
Confirmation of a PAC predicted change in the TLE2 gene in GBM60. The nucleotide substitution overlaps with individual probes of the probe set.
doi:10.1371/journal.pone.0003007.g006
Cancer Gene Identification
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outlier exons requires their transcript expression level to be within
the linear detection range of the exon array, which is determined
by their transcript expression level as well as the hybridization
efficiency and specificity of the probe sets involved. The
constituency of the test samples is another consideration,
particularly when both mutant and wild-type transcripts may be
expressed. For example, the breast cancer cell line cohort included
two splice site mutants that escaped detection by PAC because
each had a second transcript length of major intensity that resulted
from cryptic splicing (BRCA1 c.5396+1G.A in MDA-MB-436
[14] and p16 c.150+2T.C in MDA-MB-436 (Nagel et al.,
submitted for publication). Furthermore, PAC detection of the
EGFRvIII transcript isoform in clinical glioblastomas was deter-
mined by the overall expression level of EGFR transcripts, that was
near the limits of linear detection in all five EGFRvIII
glioblastomas, but also by the ratio of the EGFRvIII isoform
versus wild-type EGFR transcripts (Fig. 3B). A corollary is that
PAC performance may be compromised in detecting an outlier
exon when wild-type transcripts represent more than one-fourth of
all transcripts of that particular gene, which could be the case in
tumor samples with less than 75% neoplastic cells. However,
expression levels of mutant and wild-type alleles typically are
disproportional to their allele frequency and detection by PAC
thus again is determined by the (relative) expression level of the
outlier transcript. PAC therefore performs best in the absence of
wild-type transcript expression. Homozygous transcripts are
predominantly found among tumor suppressor genes, where often
one allele is mutated accompanied by loss of the other allele.
The influence of allele ratios was further stressed in our
simulations of recurrent outlier detection by PAC: The EGFRvIII
isoform in GBM67 was detected only once it was present as a
unique outlier among 14 samples, whereas it had not been
detected in our original PAC screen that included five other
EGFRvIII expressing glioblastomas (Fig. 4A). However, this sub
optimal PAC performance appeared not related to the recurrence
of outliers, as recurrent outliers were easily identified among cell
lines 2 even when present in five out of six cell lines (Fig. 4B). The
simulation experiments also revealed that two cell lines were
sufficient to reliably detect outlier exons and that more than eight
cell lines did not further improve PAC performance, whereas for
clinical tumor samples ten appeared the minimum but twenty
would be preferred (Fig. 4).
How efficient might PAC be in detecting mutations in cancer
genomes? From our selection of outlier exons, we identified ,20%
(21/112) SNPs, ,2% (2/112) novel base changes and ,2% (2/
112) exon skipping events. When including all nucleotide
substitutions, the false positive rate in these experiments is
,76%. By extension, amplification and sequencing 1,763
reactions on a single sample (all outliers at PAC values ,24.0)
can be expected to yield as much as 34 novel base changes and 34
exon skipping events. Therefore, our approach can be classified as
a highly efficient screening method for candidate cancer genes,
especially when compared to random selection of exons.
Additional studies should then be performed to determine whether
identified changes are causal for the tumor formation and/or
progression, for example by screening for additional mutations
(e.g. deletions, missense mutations) in other tumor samples or by
functional analysis of the identified mutants.
Materials and Methods
Samples
Our collection of 41 publicly-available human breast cancer cell
lines had been subjected to mutational screens of seven tumor
suppressor genes: BRCA1 (Breast Cancer Susceptibility Gene 1;
OMIM 113705), CDH1 (E-cadherin; OMIM 192090), MAP2K4
(MAP Kinase Kinase 4, a.k.a. MKK4; OMIM 601335), PTEN
(Phosphatase and Tensin Homolog; OMIM 601728), p16 (CDK4-
inhibitor, a.k.a. INK4A, CDKN2A; OMIM 600160), p53 (Tumor
Protein p53; OMIM 191170) and RB1 (Retinoblastoma Suscepti-
bility Gene 1; OMIM 180200) [14–18] (Nagel et al. submitted for
publication). Mutational analysis involved sequencing the entire
coding region of these genes on genomic DNA as well as analysis of
the encoded transcript. The twelve breast cancer cell lines used for
this study were: CAMA-1, EVSA-T, HCC1937, MDA-MB-134VI,
MDA-MB-157, MDA-MB-435s, MDA-MB-436, MDA-MB-453,
MDA-MB-468, MPE600, OCUB-F and SK-BR-5. Clinical
glioblastoma specimens were frozen in liquid nitrogen immediately
upon surgical resection from patients at Erasmus University
Medical Center, as described elsewhere [13]. Pathological review
revealed at least 70% tumor nuclei for each specimen. Mutation
analysis of the EGFR oncogene (Epidermal Growth Factor
Receptor; OMIM 131550) in the glioblastomas was performed by
conventional RT-PCR and subsequent sequencing of transcripts
from samples with EGFR amplifications. EGFR transcript expression
was quantified by Real-Time RT-PCR, using primers that
amplified exons 2–3 or exons 22–23 and thus allowed discrimina-
tion of wild-type EGFR transcripts and the EGFRvIII isoform.
Exon-level expression profiling
Total RNA was isolated using the Qiagen RNeasy kit for the
breast cancer cell lines and using Trizol followed by RNeasy for
the glioblastoma specimens [23]. RNA quality was assessed using
the Agilent Bioanalyser, requiring RNA integrity .7.0 [24]. All
further processing of the samples was performed according the
Affymetrix GeneChip Whole Transcript (WT) Sense Target
Labeling Assay. Affymetrix GeneChip Human Exon 1.0 ST
Arrays were used to determine the expression level of virtually all
exons present in the human genome (1.4 million probe sets
covering .1 million exon clusters). For this study, we used
expression data of the 290,000 core probe sets that are supported
by putative full-length mRNA from e.g. the RefSeq database (Geo
dataset accession number GSE9385) . Signal processing was
performed after sketch normalization by using Affymetrix ExACT
1.2.1 software and the PLIER algorithm, described in Affymetrix
GeneChip Exon Array Whitepaper ‘‘Gene Signal Estimates from
Exon Arrays’’ and Technote ‘‘Guide to Probe Logarithmic
Intensity Error (PLIER) Estimation’’ (www.affymetrix.com/sup-
port/technical).
PAttern based Correlation (PAC)
Predicted exon expression levels were calculated by using the
PAC algorithm, described in Whitepaper ‘‘Alternative Transcript
Analysis Methods for Exon Arrays’’, where the predicted
expression level of the exon (Exon-pr) equals the overall expression
of its transcript in that sample (Transcript-m: the meta probe set
expression level) multiplied by the average expression level of that
exon among all samples (Exon-ave) and divided by the average
overall expression of the transcript among all samples (Transcript-
ave), all 2-logarithm transformed. In formula:
2^log ½Exon pr~2^log ½Transcriptm
2^log ½Exonave=2^log ½Transcriptave:
PAC values were calculated by subtracting the predicted
expression level of the exon in that sample from its measured
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expression level (Exon-m), again with 2-logarithm transformation:
PAC value~2^log ½Exonm  2^log ½Exon pr:
Meta probe set expression levels were calculated using all core
probe sets of a transcript with PLIER signal estimates .50. To
enrich for probe sets with significant expression above back-
ground, PAC values were calculated using exons and transcripts
that had PLIER signal estimates .50 [13]. Identification of outlier
exons was performed without prior knowledge of the mutation
data.
Supporting Information
Table S1 Complete list of outlier exons at PAC values ,22.0
Found at: doi:10.1371/journal.pone.0003007.s001 (13.64 MB
XLS)
Table S2 Summary of PCR confirmation results for a randomly
selected cohort of outlier exons
Found at: doi:10.1371/journal.pone.0003007.s002 (0.04 MB
XLS)
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